Key summary of German national treatment guidance for hospitalized COVID-19 patients : Key pharmacologic recommendations from a national German living guideline using an Evidence to Decision Framework (last updated 17.05.2021).
COVID-19
Living guideline
Living meta-analysis
SARS-CoV-2
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
24
05
2021
accepted:
19
06
2021
pubmed:
7
7
2021
medline:
3
2
2022
entrez:
6
7
2021
Statut:
ppublish
Résumé
This executive summary of a national living guideline aims to provide rapid evidence based recommendations on the role of drug interventions in the treatment of hospitalized patients with COVID-19. The guideline makes use of a systematic assessment and decision process using an evidence to decision framework (GRADE) as recommended standard WHO (2021). Recommendations are consented by an interdisciplinary panel. Evidence analysis and interpretation is supported by the CEOsys project providing extensive literature searches and living (meta-) analyses. For this executive summary, selected key recommendations on drug therapy are presented including the quality of the evidence and rationale for the level of recommendation. The guideline contains 11 key recommendations for COVID-19 drug therapy, eight of which are based on systematic review and/or meta-analysis, while three recommendations represent consensus expert opinion. Based on current evidence, the panel makes strong recommendations for corticosteroids (WHO scale 5-9) and prophylactic anticoagulation (all hospitalized patients with COVID-19) as standard of care. Intensified anticoagulation may be considered for patients with additional risk factors for venous thromboembolisms (VTE) and a low bleeding risk. The IL-6 antagonist tocilizumab may be added in case of high supplemental oxygen requirement and progressive disease (WHO scale 5-6). Treatment with nMABs may be considered for selected inpatients with an early SARS-CoV-2 infection that are not hospitalized for COVID-19. Convalescent plasma, azithromycin, ivermectin or vitamin D For COVID-19 drug therapy, there are several options that are sufficiently supported by evidence. The living guidance will be updated as new evidence emerges.
Identifiants
pubmed: 34228347
doi: 10.1007/s15010-021-01645-2
pii: 10.1007/s15010-021-01645-2
pmc: PMC8259552
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
93-106Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
World Health Organization (WHO) Handbook for guideline development 2nd edition. 2021. https://www.who.int/publications/guidelines/handbook_2nd_ed.pdf?ua=1 . (Accessed 18 May 2021).
Moberg J, Oxman AD, Rosenbaum S, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018;16:45. https://doi.org/10.1186/s12961-018-0320-2 .
doi: 10.1186/s12961-018-0320-2
pubmed: 5975536
pmcid: 5975536
AWMF. S3 Leitlinie Empfehlungen zur stationären Therapie von Patienten mit COVID-19 (Registernummer 113-001). Assoc Scient Med Soc Germany (AWMF). https://www.awmf.org/leitlinien/detail/ll/113-001.html . (Accessed 10 May 2021).
Kluge S, Janssens U, Welte T, et al. Recommendations for critically ill patients with COVID-19. Med Klin Intensivmed Notfmed. 2020;115:175–7. https://doi.org/10.1007/s00063-020-00674-3 .
doi: 10.1007/s00063-020-00674-3
pubmed: 32166350
Kluge S, Janssens U, Spinner CD, et al. Clinical practice guideline: recommendations on inpatient treatment of patients with COVID-19. Dtsch Arztebl Int. 2021. https://doi.org/10.3238/arztebl.m2021.0110 .
doi: 10.3238/arztebl.m2021.0110
pubmed: 34789365
pmcid: 8372771
World Health Organization (WHO) - Working Group on the Clinical_Characterisation and Management of Covid-infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–7. https://doi.org/10.1016/S1473-3099(20)30483-7 .
doi: 10.1016/S1473-3099(20)30483-7
MagicApp. MAGIC Foundation. https://app.magicapp.org . (Accessed 20 May 2021).
Association of the Scientific Medical Societies in Germany (AWMF). AWMF guidance manual and rules for guideline development, 2nd Edition 2020. https://www.awmf.org/leitlinien/awmf-regelwerk/awmf-publikationen-zu-leitlinien/leitlinien-manual.html . (Accessed 20 May 2021).
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2021436 .
doi: 10.1056/NEJMoa2021436
pubmed: 32678530
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–16. https://doi.org/10.1001/jama.2020.17021 .
doi: 10.1001/jama.2020.17021
pubmed: 32876695
Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020. https://doi.org/10.1183/13993003.02808-2020 .
doi: 10.1183/13993003.02808-2020
pubmed: 32943404
pmcid: 7758541
Dequin PF, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically Ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298–306. https://doi.org/10.1001/jama.2020.16761 .
doi: 10.1001/jama.2020.16761
pubmed: 32876689
Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb Placebo-controlled Trial. Clin Infect Dis. 2021;72:e373–81. https://doi.org/10.1093/cid/ciaa1177 .
doi: 10.1093/cid/ciaa1177
pubmed: 32785710
Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–29. https://doi.org/10.1001/jama.2020.17022 .
doi: 10.1001/jama.2020.17022
pubmed: 32876697
pmcid: 7489418
Hermine O, Mariette X, Tharaux PL, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32–40. https://doi.org/10.1001/jamainternmed.2020.6820 .
doi: 10.1001/jamainternmed.2020.6820
pubmed: 33080017
Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30. https://doi.org/10.1056/NEJMoa2030340 .
doi: 10.1056/NEJMoa2030340
pubmed: 33332779
Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24–31. https://doi.org/10.1001/jamainternmed.2020.6615 .
doi: 10.1001/jamainternmed.2020.6615
pubmed: 33080005
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–44. https://doi.org/10.1056/NEJMoa2028836 .
doi: 10.1056/NEJMoa2028836
pubmed: 33085857
Veiga VC, Prats J, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84. https://doi.org/10.1136/bmj.n84 .
doi: 10.1136/bmj.n84
pubmed: 33472855
Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384:1491–502. https://doi.org/10.1056/NEJMoa2100433 .
doi: 10.1056/NEJMoa2100433
pubmed: 33631065
Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503–16. https://doi.org/10.1056/NEJMoa2028700 .
doi: 10.1056/NEJMoa2028700
pubmed: 33631066
Peter W, Horby MC, Staplin N, Spata E, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–45. https://doi.org/10.1016/S0140-6736(21)00676-0 .
doi: 10.1016/S0140-6736(21)00676-0
Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9:511–21. https://doi.org/10.1016/S2213-2600(21)00081-3 .
doi: 10.1016/S2213-2600(21)00081-3
pubmed: 33676589
pmcid: 8078880
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2007764 .
doi: 10.1056/NEJMoa2007764
pubmed: 33306283
pmcid: 7745180
Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511. https://doi.org/10.1056/NEJMoa2023184 .
doi: 10.1056/NEJMoa2023184
pubmed: 33264556
Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020. https://doi.org/10.1001/jama.2020.16349 .
doi: 10.1001/jama.2020.16349
pubmed: 32821939
pmcid: 7442954
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–78. https://doi.org/10.1016/s0140-6736(20)31022-9 .
doi: 10.1016/s0140-6736(20)31022-9
pubmed: 32423584
pmcid: 32423584
Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2015301 .
doi: 10.1056/NEJMoa2015301
pubmed: 33156580
pmcid: 7377062
World Health Organization (WHO). COVID-19 Clinical management Living guidance 2021. https://apps.who.int/iris/rest/bitstreams/1328457/retrieve . (Accessed 20 May 2021).
Simonis A, Theobald SJ, Fätkenheuer G, et al. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Mol Med. 2020. https://doi.org/10.15252/emmm.202013105 .
doi: 10.15252/emmm.202013105
pubmed: 33015938
pmcid: 7646058
Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460–70. https://doi.org/10.1001/jama.2020.10044 .
doi: 10.1001/jama.2020.10044
pubmed: 32492084
Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371: m3939. https://doi.org/10.1136/bmj.m3939 .
doi: 10.1136/bmj.m3939
pubmed: 33093056
Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–29. https://doi.org/10.1056/NEJMoa2031304 .
doi: 10.1056/NEJMoa2031304
pubmed: 33232588
Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. Egypt J Anaesth. 2020;36:264–72. https://doi.org/10.1080/11101849.2020.1842087 .
doi: 10.1080/11101849.2020.1842087
Lundgren JD, Grund B, Barkauskas CE, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384:905–14. https://doi.org/10.1056/NEJMoa2033130 .
doi: 10.1056/NEJMoa2033130
pubmed: 33356051
Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–51. https://doi.org/10.1056/NEJMoa2035002 .
doi: 10.1056/NEJMoa2035002
pubmed: 33332778
Chen P, Nirula A, Heller B, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–37. https://doi.org/10.1056/NEJMoa2029849 .
doi: 10.1056/NEJMoa2029849
pubmed: 33113295
Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–44. https://doi.org/10.1001/jama.2021.0202 .
doi: 10.1001/jama.2021.0202
pubmed: 33475701
pmcid: 7821080
U.S. Food and Drug Administration (FDA). Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab. www.fda.gov/media/145802/download . (Accessed 12 May 2021).
Association of the Scientific Medical Societies in Germany (AWMF). S3-Leitlinie prophylaxe der venösen thromboembolie (VTE). https://www.awmf.org/leitlinien/detail/ll/003-001.html . (Accessed 12 May 2021).
Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020;173:268–77. https://doi.org/10.7326/m20-2003 .
doi: 10.7326/m20-2003
pubmed: 32374815
Langer F, Kluge S, Klamroth R, et al. Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie. 2020;40:264–9. https://doi.org/10.1055/a-1178-3551 .
doi: 10.1055/a-1178-3551
pubmed: 32498097
pmcid: 7416221
Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–9. https://doi.org/10.1136/bmj.38733.466748.7C .
doi: 10.1136/bmj.38733.466748.7C
pubmed: 16439370
pmcid: 1363908
Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341:793–800. https://doi.org/10.1056/nejm199909093411103 .
doi: 10.1056/nejm199909093411103
pubmed: 10477777
Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–9. https://doi.org/10.1161/01.Cir.0000138928.83266.24 .
doi: 10.1161/01.Cir.0000138928.83266.24
pubmed: 15289368
Patell R, Chiasakul T, Bauer E, et al. Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis. Thromb Haemost. 2021;121:76–85. https://doi.org/10.1055/s-0040-1721664 .
doi: 10.1055/s-0040-1721664
pubmed: 33378787
Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995–2002. https://doi.org/10.1111/jth.14888 .
doi: 10.1111/jth.14888
pubmed: 32369666
pmcid: 7497052
Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50. https://doi.org/10.1016/j.thromres.2020.04.041 .
doi: 10.1016/j.thromres.2020.04.041
pubmed: 32381264
pmcid: 32381264
Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs. standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325:1620–30. https://doi.org/10.1001/jama.2021.4152 .
doi: 10.1001/jama.2021.4152
pubmed: 33734299
Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation in non-critically Ill patients with Covid-19. medrXiv. 2021. https://doi.org/10.1101/2021.05.13.21256846 .
doi: 10.1101/2021.05.13.21256846
Abaleke E, Abbas M, Abbasi S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:605–12. https://doi.org/10.1016/S0140-6736(21)00149-5 .
doi: 10.1016/S0140-6736(21)00149-5
Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396:959–67. https://doi.org/10.1016/S0140-6736(20)31862-6 .
doi: 10.1016/S0140-6736(20)31862-6
pubmed: 32896292
pmcid: 32896292
Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2019014 .
doi: 10.1056/NEJMoa2019014
pubmed: 33264542
pmcid: 7397242
Sekhavati E, Jafari F, SeyedAlinaghi S, et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. Int J Antimicrob Agents. 2020;56: 106143. https://doi.org/10.1016/j.ijantimicag.2020.106143 .
doi: 10.1016/j.ijantimicag.2020.106143
pubmed: 32853672
pmcid: 32853672
Dalhoff K, Abele-Horn M, Andreas S, et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia - update 2017. Pneumologie. 2018;72:15–63. https://doi.org/10.1055/s-0043-121734 .
doi: 10.1055/s-0043-121734
pubmed: 29341032
Ewig S, Höffken G, Kern WV, et al. Management of adult community-acquired pneumonia and prevention - Update 2016. Pneumologie. 2016;70:151–200. https://doi.org/10.1055/s-0042-101873 .
doi: 10.1055/s-0042-101873
pubmed: 26926396
Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label. Multicentre Trial. 2021. https://doi.org/10.2139/ssrn.3714649.Accessed20May .
doi: 10.2139/ssrn.3714649.Accessed20May
Carlos C, Aina C, Andres Blanco-Di M, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. Res Square. 2021. https://doi.org/10.21203/rs.3.rs-116547/v1 .
doi: 10.21203/rs.3.rs-116547/v1
Ravikirti RR, Pattadar C, et al. Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo-controlled trial. medrXiv. 2021. https://doi.org/10.1101/2021.01.05.21249310 .
doi: 10.1101/2021.01.05.21249310
Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021;103:214–6. https://doi.org/10.1016/j.ijid.2020.11.191 .
doi: 10.1016/j.ijid.2020.11.191
pubmed: 33278625
pmcid: 33278625
Jermain B, Hanafin PO, Cao Y, et al. Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. J Pharm Sci. 2020;109:3574–8. https://doi.org/10.1016/j.xphs.2020.08.024 .
doi: 10.1016/j.xphs.2020.08.024
pubmed: 32891630
pmcid: 7473010
Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203: 105751. https://doi.org/10.1016/j.jsbmb.2020.105751 .
doi: 10.1016/j.jsbmb.2020.105751
pubmed: 32871238
pmcid: 7456194
Ginde AA, Brower RG, Caterino JM, et al. Early high-dose vitamin D(3) for critically Ill, vitamin D-deficient patients. N Engl J Med. 2019;381:2529–40. https://doi.org/10.1056/NEJMoa1911124 .
doi: 10.1056/NEJMoa1911124
pubmed: 31826336
Murai IH, Fernandes AL, Sales LP, et al. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA. 2021;325:1053–60. https://doi.org/10.1001/jama.2020.26848 .
doi: 10.1001/jama.2020.26848
pubmed: 33595634
Deutsche Gesellschaft für Ernährung E. V. (DGE). Zum Zusammenhang zwischen der Vitamin-D-Zufuhr bzw. dem Vitamin-D-Status und dem Risiko für eine SARS-CoV-2-Infektion sowie der Schwere des Verlaufs einer COVID-19-Erkrankung – ein Überblick über die aktuelle Studienlage (Stand 11. Januar 2021). www.dge.de/uploads/media/DGE_Fachinfo_VitaminD_COVID-19_Stand_Januar_2021.pdf . (Accessed 12 May 2021).
Malin JJ, Suárez I, Priesner V, et al. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34:e00162-e220. https://doi.org/10.1128/cmr.00162-20 .
doi: 10.1128/cmr.00162-20
pubmed: 33055231
pmcid: 7566896
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795–807. https://doi.org/10.1056/NEJMoa2031994 .
doi: 10.1056/NEJMoa2031994
pubmed: 33306283
pmcid: 33306283